Claudin 18.2-CAR-T cell therapy - CARsgen

Drug Profile

Claudin 18.2-CAR-T cell therapy - CARsgen

Alternative Names: Anti-Claudin18.2-CAR-T cell therapy - CARsgen; CAR-CLD18 T cell therapy - CARsgen; Claudin18.2-redirected Autologous Cells - CARsgen; CLD18-CAR-T cell therapy - CARsgen

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CARsgen
  • Developer CARsgen; Changhai Hospital of Shanghai
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastric cancer; Pancreatic cancer

Most Recent Events

  • 05 Oct 2017 Carsgen plans a phase I trial for Claudin 18.2-CAR-T cell therapy for Pancreatic cancer and Gastric cancer (In adults, In the elderly) in China (NCT03302403)
  • 10 Aug 2017 Phase-I clinical trials in Gastric cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)
  • 10 Aug 2017 Phase-I clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top